The head-to-head question is now answered at trial scale: SURMOUNT-5 reported significantly greater weight reduction with tirzepatide than semaglutide at matched treatment intent. Real-world cohort data has landed in the same direction.
The nuances matter. Discontinuation rates, tolerability profiles, and cost/access considerations narrow the practical gap, and semaglutide’s cardiovascular-outcomes evidence base remains deeper. For diabetes-specific endpoints the comparison is closer than for weight.
Both compounds dominate our gray-market testing volume, and both attract counterfeits — identity verification remains the first thing we check on every GLP-1 specimen.
